Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
GYRE THERAPEUTICS, INC. amended CVR Agreement Amendment (effective 2023-03-29).
- Action
- amendment
- Effective
- 2023-03-29
Exact text from the filing
On March 29, 2023, Catalyst executed an amendment to Contingent Value Rights Agreement (the “ CVR Agreement Amendment ”) to the previously announced Contingent Value Rights Agreement, dated as of December 26, 2022 (the “ CVR Agreement ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
GYRE THERAPEUTICS, INC. amended Agreement and Amendment with Catalyst, GNI Group and GNI HK (effective 2023-03-29).
- Action
- amendment
- Agreement
- asset purchase
- Counterparty
- Catalyst, GNI Group and GNI HK
- Effective
- 2023-03-29
Exact text from the filing
On March 29, 2023, Catalyst, GNI Group and GNI HK entered into an agreement and amendment (the “ Agreement and Amendment ”) to the previously announced Asset Purchase Agreement, dated as of December 26, 2022 (the “ F351 Agreement ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
GYRE THERAPEUTICS, INC. amended BCA Amendment with Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the Minority Holders, and Continent Pharmaceuticals Inc. (effective 2023-03-29).
- Action
- amendment
- Agreement
- merger
- Counterparty
- Catalyst Biosciences, Inc., GNI USA, Inc., GNI Group Ltd., GNI Hong Kong Limited, Shanghai Genomics, Inc., the Minority Holders, and Continent Pharmaceuticals Inc.
- Effective
- 2023-03-29
Exact text from the filing
On March 29, 2023, Catalyst Biosciences, Inc., a Delaware corporation (“ Catalyst ”), GNI USA, Inc., a Delaware corporation (“ GNI USA ”), GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (“ GNI Group ”), GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (“ GNI HK ”), Shanghai Genomics, Inc., a company organized under the laws of the People’s Republic of China (“ Shanghai Genomics ”, and collectively with GNI USA, GNI Group and GNI HK, the “ Contributors ,” and each a “ Contributor ”), the individuals (each, a “ Minority Holder ” and collectively, the “ Minority Holders ”) listed on Annex A thereto and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (the “ CPI ”), entered into an amendment (the “ BCA Amendment ”) to the previously announced Business Combination Agreement, dated as of December 26, 2022 (the “ Business Combination Agreement ”).
View on SEC.gov